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Abstract  
Autosomal polycystic kidney disease (ARPKD) is 
associated with progressive enlargement of the kidneys 
fuelled by the formation and expansion of fluid-filled cysts. 
The disease is congenital and children that do not 
succumb to it during the neonatal period will, by age 10 
years, more often than not, require nephrectomy+renal 
replacement therapy for management of both pain and 
renal insufficiency. Since increasing cystic index (CI; 
percent of kidney occupied by cysts) drives both renal 
expansion and organ dysfunction, management of these 
patients, including decisions such as elective nephrectomy and prioritization on the transplant waitlist, could 
clearly benefit from serial determination of CI. So also, clinical trials in ARPKD evaluating the efficacy of novel 
drug candidates could benefit from serial determination of CI. Although ultrasound is currently the imaging 
modality of choice for diagnosis of ARPKD, its utilization for assessing disease progression is highly 
limited. Magnetic resonance imaging or computed tomography, although more reliable for determination of CI, 
are expensive, time-consuming and somewhat impractical in the pediatric population. Using a well-established 
mammalian model of ARPKD, we undertook a big data-like analysis of minimally- or non-invasive serum and 
urine biomarkers of renal injury/dysfunction to derive a family of equations for estimating CI. We then applied a 
signal averaging protocol to distill these equations to a single empirical formula for calculation of CI. Such a 
formula will eventually find use in identifying and monitoring patients at high risk for progressing to end-stage 
renal disease and aid in the conduct of clinical trials.     
 
ARPKD
Cysts 
NGAL Serum 
0.178157234
%CI=(0.32*BUN(mg/dL))+(17.9*SCr(mg/dL))+(456*urine IL18(μg)) - 2.18
The Nieto-Narayan Formula
KIM-1
Kidney Body Mass Ratio
blood & urine
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Introduction 
Autosomal recessive polycystic kidney disease (ARPKD) is a genetic disorder caused by a mutation in the 
polycystic kidney and hepatic disease 1 (PKHD1) gene and affects ~ 1 in 20,000 children [1-4]. Fluid-filled cyst 
formation and expansion replaces normal tissue and progressively increases kidney size [5,6]. Nevertheless, 
owing to the remarkable degree to which intact nephrons can compensate for loss of functioning parenchyma, 
glomerular function rate measurements fail to disclose the increasing cystic index (CI; percent of kidney 
occupied by cysts) until late in the disease [6]. In ARPKD, dialysis+nephrectomy and/or kidney transplantation 
are inevitable and are driven, both, by the need for pain management via renal volume reduction and 
restitution of renal function. 
 
Aggressive use of available therapies (e.g. blood pressure lowering drugs) has improved survival in ARPKD. 
While 20-30% of infants with the disease still die hours or days after birth due to breathing difficulties, of those 
that survive infancy, ~ 82% survive to age 10 and ~ 73% live past the age of 15 years [3,4]. Management of 
this patient population including decisions such as elective nephrectomy and prioritization on the transplant 
waitlist could clearly benefit from serial determination of CI, the key driver of increased kidney volume and 
(eventual) renal failure. So also, clinical trials in ARPKD evaluating efficacy of novel drug candidates could 
clearly benefit from serial measurements of CI [7].  Although ultrasound is currently the imaging modality of 
choice for a diagnosis of ARPKD, its utilization for assessing disease progression is limited [8]. Due to the 
irregular shape and enormous number of cysts, only computed tomography (CT) or magnetic resonance 
imaging (MRI) can accurately measure cyst content [8]. Unfortunately such contrast-enhanced scanning 
modalities are expensive, time-consuming and somewhat impractical in the pediatric population. 
 
In a well-established mammalian model of ARPKD [9,10], we have previously [9] determined CI while 
evaluating serum and urine levels of several renal injury/dysfunction biomarkers. We queried this database to 
identify and quantify a relationship, if any, between CI and this family of biomarkers.   
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Methods 
Source Data: No animals were used in the analysis of these data. Rather, all data analyzed in this study were 
sourced from a previously published study [9] characterizing a rodent model of ARPKD. In that study [9], male 
PCK (PCK/CrljCrl-Pkhd1pck/Crl) rats carrying the PKHD1 mutation for ARPKD, had 1 kidney removed at ~10.5 
weeks of age to accelerate renal dysfunction. Animals were sacrificed at age 13.5 weeks. Immediately prior to 
sacrifice, 24 hr urine was collected in metabolic cages and animals weighed. Blood was drawn at sacrifice and 
the kidney retrieved for analysis. Levels of a panel of kidney-relevant biomarkers [see Table 1] were analyzed 
using either enzyme-linked immunoabsorbent assay (ELISA), a core services laboratory (Northwell Health, NY) 
or biochemical assays [9]. Concentration of urine biomarkers were multiplied by 24 hr urine volume. CI (% cyst 
space/renal parenchyma) was measured from hematoxylin and eosin (H&E)-stained renal sections (two 
separate sections per kidney) by two independent observers and the values averaged so as to get a 
representative CI value for the kidney.  
Correlation Coefficient Criteria: Microsoft Excel 2010 curve fitting software was used to generate plots of CI 
against renal mass, renal:body mass ratio and biomarker levels. For a given CI, if a corresponding biomarker 
level was missing, that pair was eliminated from the analysis. Final n values for each correlation are reported in 
Table 1. Correlation coefficient r, i.e. the simultaneous fluctuation occurring between two variables, was 
calculated from r2 values generated off the trend line fitted using exponential, linear, logarithmic or polynomial 
regression. To determine whether r was significant, the r value and the sample size n were entered into an 
online calculator [11]. A p value <0.05 was deemed significant. An r > 0.7 with a p<0.05 was used as the lower 
limit for CI vs. biomarker correlation.  
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Results 
Table 1 reports the variables, including biomarkers, correlated with CI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Individual values for CI, kidney mass, kidney to body mass ratio and the biomarkers evaluated are listed in 
Table 2. We queried these source data to draw out and quantify relationships, if any, between CI and 
biomarkers. 
 
 
 
 
 
%CI
Variable/Biomarker Datapoints (n)
kidney mass (g) 27
kidney/body mass ratio 27
 NGAL, serum (µg/mL)  and urine (µg) 24 and 25
KIM-1, urine  (µg) 12
Cystatin C,  serum  (µg/mL) and urine  (µg) 25 and 24
IL-18, serum  (µg/mL) and urine  (µg) 27 and 23
SCr  (mg/dL) 27
BUN  (mg/dL) 27
proteinuria (mg) 24
microalbuminuria (µg) 24
Table 1: CI and Renal Variables/Biomarkers. CI was correlated with kidney mass, kidney/body mass 
ratio and serum and/or urine-based renal biomarkers including neutrophil gelatinase-associated 
lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1), Cystatin C, interleukin (IL)-18, serum creatinine 
(SCr), blood urea nitrogen (BUN), proteinuria and microalbuminuria. The n represents the number of 
datapoints available for a given biomarker and CI set. 
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%
CI
kidney m
ass (g)
kidney/body m
ass
NGAL, serum (µg/mL)
NGAL, urine (µg)
KIM-1 urine (µg/mL)
Cystatin C, serum (µg/mL)
Cystatin C urine (µg)
IL-18, serum (µg/mL)
IL-18, urine (µg)
SCr (mg/dL)
BUN (mg/dL)
proteinuria (mg)
microalbuminuria (µg)
27.5792
6.7300
1.7526
NA
960.00
0.002688579
0.5727088
14.998287
0.000034
0.005328081
0.61
0.61
427.73
72.02727
30.3611
6.7500
1.6504
3.99
1088.00
0.002684102
1.129012
3.438369
0.000027
0.011396997
0.62
0.62
489.05
61.366056
30.9221
7.6000
1.8225
1.54
120.18
0.00285067
1.4828816
14.5136376
0.000032
0.009516466
0.78
0.78
434.90
79.9212015
34.4874
7.2500
1.6477
0.86
73.92
0.003310386
1.1168876
7.8273184
0.000078
0.020001416
0.5
0.5
527.10
91.843422
20.9282
5.4000
1.2135
0.71
168.53
0.002530843
1.3691936
9.644064
0.000026
0.005473673
0.48
0.48
563.21
104.99436
26.2359
7.1100
1.6969
1.18
636.69
0.002982213
0.7928976
13.8921356
0.000036
0.006371703
0.49
0.49
409.87
55.147743
23.7730
5.5400
1.3781
1.28
629.03
0.004386883
1.8374668
14.6956032
0.000085
0.013753793
0.53
0.53
782.75
125.102412
26.0932
5.7300
1.2140
1.05
63.54
0.002830051
0.9828504
21.323152
0.000100
0.009541357
0.54
0.54
618.30
134.44605
22.0227
4.8000
1.1241
1.05
416.73
0.00480303
1.2236956
23.996291
0.000056
0.008970211
0.49
0.49
562.65
113.025105
19.8303
5.0600
1.2650
0.82
206.11
0.003438274
1.3144648
0.4081704
0.000016
0.007020066
0.53
0.53
389.92
70.39584
19.6681
6.1600
1.3391
0.97
70.90
0.004766574
1.0021896
16.7835192
0.000066
0.007412596
0.56
0.56
799.80
173.22354
15.4724
6.0500
1.4975
3.06
1216.00
0.004947137
1.8639308
19.4514438
0.000037
0.005764512
0.58
0.58
752.99
121.265334
21.0398
8.4100
1.9835
3.38
NA
NA
1.4352892
NA
0.000049
NA
0.63
0.63
NA
NA
25.2383
7.0000
1.9391
NA
NA
NA
2.4615308
NA
0.000134
NA
0.77
0.77
NA
NA
23.7605
6.7700
1.5671
NA
384.00
NA
1.3336624
3.7887408
0.000065
0.005986509
0.58
0.58
143.81
23.824395
11.5877
3.6200
0.9211
1.92
432.01
NA
1.1168876
0.28284336
0.000048
NA
0.38
0.38
188.85
35.212266
5.9299
3.2800
0.8367
0.80
39.76
NA
0.9746564
0.09850332
0.000019
0.002081549
0.43
0.43
138.42
30.274965
0.4484
3.4900
0.8135
0.73
65.88
NA
0.670196
2.923987
0.000022
NA
0.33
0.33
307.97
67.96251
17.3568
5.0900
1.1211
1.08
66.85
NA
0.5895676
0.178682208
0.000026
0.00268384
0.47
0.47
208.96
50.052042
3.8756
4.0000
0.9412
2.01
381.62
NA
0.6841508
3.8166282
0.000056
0.001771726
0.38
0.38
287.14
47.789838
7.5341
5.3000
1.2619
1.17
133.07
NA
1.4617588
0.10813803
0.000119
0.001387699
0.54
0.54
147.88
25.6407375
18.9592
4.9800
1.1116
1.78
35.91
NA
1.2026532
1.46491344
0.000049
0.002186404
0.52
0.52
260.17
35.500815
18.0817
5.7100
1.4134
1.70
355.69
NA
0.55031
4.188086
0.000074
0.002382867
0.55
0.55
238.80
31.93545
16.8749
7.7400
1.7671
1.25
184.60
NA
1.656142
7.4632298
0.000021
0.002955052
0.58
0.58
292.41
36.658869
13.7136
5.6100
1.2249
1.21
40.07
NA
NA
0.254075
0.000062
0.0019058
0.56
0.56
215.03
41.81178
10.6465
4.5200
1.0660
1.44
300.97
NA
0.88
8.1518544
0.000032
0.002226449
0.38
0.38
252.14
61.5282885
12.0326
5.9400
1.2122
1.24
NA
NA
NA
NA
0.000025
NA
0.46
0.46
NA
NA
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 Since an increasing CI or ARPKD disease progression results in kidney enlargement and increased kidney 
mass [5], we first sought to confirm such a relationship between kidney mass and CI in this ARPKD dataset. As 
seen in Figures 1A and 1B, an excellent correlation is observed between CI and kidney mass. While the data 
could theoretically be fit by a number of regression strategies, each yielding an r > 0.7 and a p<0.01 (Figure 
1B), a linear relation between CI and kidney mass was clearly observed. The Pearson product-moment 
correlation coefficient, r, a measure of the strength and direction of the linear relationship, yielded a value of 
0.73 with a p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: CI and Kidney Mass. CI tracks renal mass across a range of values (A).   A linear 
correlation is also observed between these 2 variables across the CI spectrum (B). 
 
0
5
10
15
20
25
30
35
40
0.00 2.00 4.00 6.00 8.00 10.00
%
C
I
kidney mass (g)
1A
1B
Regression/Type Equation r
2 
r p
Linear y = 4.63x - 8 0.53 0.73 <.01
Logarithmic y = 25.94ln(x) - 26.03 0.56 0.75 <.01
Polynomial y = -0.45x
3 + 6.64x2 - 25.85x + 34.02 0.61 0.78 <.01
Power y = 0.21x
2.47
0.49 0.70 <.01
Exponetial y = 1.31e
0.43x
0.43 0.65 <.01
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Next, CI was correlated with kidney to body mass ratio. Once again, excellent correlation was observed 
between these two variables (Figures 2A and 2B). Similar to its relation with renal mass, a linear relationship 
was observed between CI and kidney to body mass ratio with a Pearson product-moment correlation 
coefficient, r of 0.73 with a p<0.01.   
.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: CI and Kidney to Body Mass Ratio. CI tracks kidney to body mass ratio across a 
range of values (A).   A linear correlation is also observed between these 2 variables across 
the CI spectrum (B). 
 
 
0
5
10
15
20
25
30
35
40
0 0.5 1 1.5 2 2.5
%
C
I
Kidney/body mass ratio
2A
2B
Regression/Type Equation r
2 
r p
Linear y = 18.52x - 6.54 0.53 0.73 <.01
Logarithmic y = 25.72ln(x) + 11.5 0.58 0.76 <.01
Polynomial y  = -23.50x
2 + 84.13x - 49.8 0.62 0.79 <.01
Power y = 7.73x
2.42 0.49 0.70 <.01
Exponetial y = 1.58e
1.66x 0.41
0.64 <.01
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Serum and/or urine-based biomarkers of renal injury/dysfunction were then correlated with CI. The majority of 
biomarkers listed in Table 2 gave poor or no correlation with CI. An example of this is the lack of correlation 
between CI and serum Cystatin C as shown in Figures 3A and B.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
0 0.5 1 1.5 2 2.5
%
C
I
Serum Cystatin C (µg/mL)
3A
3B
Regression/Type Equation r
2 
r p
Linear y = 4.54x + 13.76 0.06 0.24 NS
Logarithmic y = 5.53ln(x) + 18.6 0.06 0.25 NS
Polynomial y = -2.15x
2 + 10.38x + 10.3 0.06 0.25 NS
Power y = 14.27x
0.76 0.11 0.33 NS
Exponetial y = 7.47e
0.61x 0.10 0.31 NS
Figure 3: CI and Serum Cystatin C. There is no correlation between CI and serum Cystatin 
C in this model of ARPKD (A and B). 
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By contrast, as seen in Figures 4, 5 and 6, BUN, SCr and 24 hr urine IL-18 values, respectively, demonstrated 
excellent correlation with CI.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
5
10
15
20
25
30
35
40
0 10 20 30 40 50
%
C
I
BUN (mg/dL)
4A
4B
Regression/Type Equation r
2 
r p
Linear y = 0.95x - 8.15 0.48 0.70 <.01
Logarithmic y = 30.3ln(x) - 81.85 0.55 0.74 <.01
Polynomial y = -0.07x
2 + 5.19x - 71.46 0.63 0.79 <.01
Power y = 0.002x
2.67 0.40 0.64 <.01
Exponetial y = 1.58e
0.08x 0.33 0.57 <.01
Figure 4: CI and BUN. CI tracks BUN across a range of values (A).  A linear correlation is 
also observed between these 2 variables across the CI spectrum (B). 
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0
5
10
15
20
25
30
35
40
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
%
C
I
SCr (mg/dL)
5A
5B
Regression/Type Equation r
2 
r p
Linear y = 53.63x - 9.66 0.44 0.66 <.01
Logarithmic y = 29.45ln(x) + 38.03 0.48 0.69 <.01
Polynomial y = -125.47x
2 + 192.12x - 46.48 0.50 0.71 <.01
Power y = 111.55x
3.04 0.49 0.70 <.01
Exponetial y = 0.95e
5.24x 0.40 0.63 <.01
Figure 5: CI and SCr. CI tracks SCr across a range of values (A).   A linear correlation is also 
observed between these 2 variables across the CI spectrum (B). 
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0 0.005 0.01 0.015 0.02 0.025
%
C
I
IL-18 (µg)
6A
6B
Regression/Type Equation r
2 
r p
Linear y = 1368x + 11.27 0.62 0.78 <.01
Logarithmic y = 9.13ln(x) + 68.56 0.73 0.85 <.01
Polynomial y = -74278x
2 + 2728.3x + 7.23 0.69 0.83 <.01
Power y = 371.29x
0.57 0.61 0.78 <.01
Exponetial y = 10.77e
79.21x 0.45 0.67 <.01
Figure 6: CI and Urine IL-18. CI tracks 24 hr urine IL-18 across a range of values (A). A  
linear correlation is also observed between these 2 variables across the CI spectrum (B). 
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Consistent with the CI and kidney mass and CI and kidney to body mass ratio correlations, a linear fit gave 
excellent correlation with CI for BUN, SCr and urine IL-18. Furthermore, the CI values observed in this study 
span a broad range from 0.4 to 35% which more than likely falls within the dynamic range of CI observed 
clinically in ARPKD survivors. Finally, at best there was only ~10% difference between the r values for the 
linear fit vs. the best fit (see Figures 4B, 5B and 6B). A slightly “better” fit was therefore sacrificed in favor of a 
linear fit as long as long as the correlation met the criteria listed under Methods. As shown in Table 3, linear 
regressions were used to generate a family of equations for calculating CI with BUN, SCr and urine IL-18 being 
the variables.   
 
 
 
 
 
 
 
 
 
 
 
Now, if,   
   𝑦 ≒ 𝑓(𝑥1),                
   𝑦 ≒ 𝑓(𝑥2),             
        and 𝑦 ≒ 𝑓(𝑥3),     
 
then it follows from the principle of signal averaging [12] that                
  
 𝑦 ≒ [𝑓(𝑥2) + 𝑓(𝑥2) + 𝑓(𝑥3)]/3     
 
 
 
 
 
 
Table 3: CI as a Function of Biomarkers. CI can be computed using any member of a family 
of equations. In these equations, the variables driving CI are BUN, SCr and 24 hr urine IL-18. 
 
y f(x)
CI 0.95 * BUN (mg/dL) - 8.15
CI 53.63 * SCr(mg/dL) - 9.66
CI 1368 * urine IL-18(µg) + 11.27
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In other words, as shown in Figure 7, using more than 1 biomarker, each of which tracks CI, results in 
increased fidelity for estimating CI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As seen in Figure 8, we have therefore condensed the family of equations in Table 3, into a single 
equation/formula viz. 
 
  %𝑪𝑰 = (𝟎. 𝟑𝟐 ∗ 𝑩𝑼𝑵(𝒎𝒈/𝒅𝑳)) + (𝟏𝟕. 𝟗 ∗ 𝑺𝑪𝒓(𝒎𝒈/𝒅𝑳)) + (𝟒𝟓𝟔 ∗ 𝒖𝒓𝒊𝒏𝒆 𝑰𝑳𝟏𝟖(𝝁𝒈))  − 𝟐. 𝟏𝟖 
 
Figure 7: CI vs a Biomarker Pair. A 3-dimensional 
scattergram showing CI as a function of SCr and BUN. A 
robust linear correlation is observed. Including urine IL-18 in 
this plot would have required an additional spatial dimension. 
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%CI=(0.32*BUN(mg/dL))+(17.9*SCr(mg/dL))+(456*urine IL18(μg)) - 2.18
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Kidney Body Mass Ratio
blood & urine
Figure 8: CI Calculator in ARPKD. Big data–like analysis of multiple blood and urine-
based biomarkers of renal injury/dysfunction yielded a calculator for estimating CI in 
ARPKD.   
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Discussion 
 
Using a big data-type analysis, we herein report for the first time a quantitative relationship between CI and the 
levels of certain serum and urine biomarkers in a model of ARPKD; this formula can be used to estimate CI.   
      
 A genetically acquired and congenital disease, ~20-30% of ARPKD patients succumb with the first 1-2 months 
of life with pulmonary insufficiency secondary to renal enlargement as the primary cause of death [1-4]. For 
children making it past that stage, improvements in health care and disease management call for nephrectomy 
+ dialysis or kidney transplant by ~ 10 years of age [6]. Intervention at this age is driven both by the need for 
reduction in flank pain due to highly enlarged kidneys as well as severe renal insufficiency. Formation and 
expansion of fluid-filled cysts drives both renal enlargement and renal insufficiency [5]. A hallmark feature of 
ARPKD is that cyst formation and renal enlargement precede the decrease in renal function [6]. This means 
that when a precipitous decline in renal function is observed, cystic damage to the renal parenchyma is severe.  
 
Today, ARPKD patients are subjected to renal imaging every so often as a means of tracking cyst formation 
and expansion. Although ultrasound is currently the imaging modality of choice for a diagnosis of ADPKD, its 
utilization for assessing disease progression is limited; i.e. ultrasound is a diagnostic but not prognosticative 
tool. Ultrasonography is highly operator-dependent and produces images that are less sensitive and 
reproducible than computed tomography (CT) or magnetic resonance imaging (MRI) [8]. Furthermore, 
ultrasound cannot reliably detect small but significant changes in kidney size or small cysts that are less than 
one centimeter in diameter. Ultrasound based measurements of kidney volume are calculated by utilizing 
parameters based on a modified ellipsoid formula. Problems related to the use of the ellipsoid formula include 
inter-operator variability when determining the maximal anterior-posterior diameter, the variability induced by 
patient respiration, and the lack of uniform cyst expansion throughout the kidney in this disease, making the 
ellipsoid a less than perfect estimation of size [8]. The contributions of these variables typically result in an 
overall underestimation of kidney volume. Measuring cyst volume is more difficult compared to total kidney 
volume. Due to the irregular shape and enormous number of cysts, only CT or MRI methods using the integral 
or voxel counting method can accurately measure cyst content [8]. Unfortunately such contrast-enhanced or 
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even simple scanning modalities are expensive, time-consuming and somewhat impractical in the pediatric 
population. Certainly, ARPKD children and their parents do not savor the experience of undergoing repeat 
contrast MRI or CT.          
 
We have previously measured the levels of several serum and urine-based biomarkers a model in a well-
accepted mammalian model of ARPKD [9,10]. The PCK rat has a mutation in the PKHD1 gene and exhibits all 
the hallmark features of human ARPKD and congenital liver fibrosis [9] i.e fibrocystic human disease. In the 
present study, we adopted a big data-like approach to identify and quantify the relation between these 
biomarkers and CI. Our findings suggest that of the biomarkers studied, BUN, SCr and urine IL-18 are of 
particularly useful in that they correlate linearly with CI across a broad range of cystic pathology. Implicit in this 
observation is that these biomarkers can potentially be used to estimate CI from the very early through the late 
disease stage.  Furthermore, since a signal averaging protocol was used to combine these 3 biomarkers, each 
of which tracks CI, the resulting formula is expected to provide increased fidelity for estimating CI. Importantly, 
from a pediatric patient perspective, serum and urine (which are routinely collected in this population)-based 
tests bring enhanced compliance when compared to time-, labor-, expense-intensive and uncomfortable 
longitudinal imaging protocols. Finally, use of a 24 hr urine sample, while somewhat cumbersome, eliminates 
any confounding factors with spot urine collection.     
 
There are some limitations to our findings. The present study used a database stemming from urine, serum 
and renal samples from 13.5 week old PCK rats. Our empirical formula can benefit from further refinement by 
use of larger database that incorporates samples from several different timepoints in the PCK rat model as well 
as other mammalian models of ARPKD such as the B6.129S6-Pkhd1 tm1Cjwa/J (Jackson Labs) mouse 
model. More importantly, the formula will eventually need to be validated in ARPKD patients. Serum and urine 
samples from nephrectomy candidates will need to be obtained and entered into the calculator and the 
calculated CI correlated with the measured CI from the discarded kidney.   
 
  Biomarker-based Calculator for ARPKD 
 
These limitations notwithstanding, our results form the foundation for developing a calculator in ARPKD along 
the lines of other existing calculators for renal and liver diseases such as the modified diet in renal disease 
 (MDRD), chronic kidney disease-epidemiology collaboration (CKD-EPI), FIB-4 and aspartate 
aminotransferase to platelet ratio index (APRI) calculators [13-15]. Such an empirical ARPKD calculator will not 
only represent a patient-friendly and relatively inexpensive method to track disease progress and aid in the 
management of this population but can also be used in clinical trials of drugs that work by reducing the 
formation and growth of cysts and therefore eventually retard renal dysfunction. 
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